TAF1A

Summary

TAF1A (TATA-box binding protein associated factor, RNA polymerase I subunit A, HGNC:11532) is a protein-coding gene on chromosome 1q41, encoding TATA box-binding protein-associated factor RNA polymerase I subunit A (Q15573). Component of the transcription factor SL1/TIF-IB complex, which is involved in the assembly of the PIC (pre-initiation complex) during RNA polymerase I-dependent transcription. It is a selective cancer dependency (DepMap: 50.4% of cell lines).

This gene encodes a subunit of the RNA polymerase I complex, Selectivity Factor I (SLI). The encoded protein is a TATA box-binding protein-associated factor that plays a role in the assembly of the RNA polymerase I preinitiation complex. Alternate splicing results in multiple transcript variants encoding multiple isoforms.

Source: NCBI Gene 9015 — RefSeq curated summary.

At a glance

• Gene–disease (curated): familial isolated dilated cardiomyopathy (Supportive, GenCC)
• GWAS associations: 1
• Clinical variants (ClinVar): 66 total
• Phenotypes (HPO): 13
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 50.4% of screened cell lines
• MANE Select transcript: NM_005681

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11532
Approved symbol	TAF1A
Name	TATA-box binding protein associated factor, RNA polymerase I subunit A
Location	1q41
Locus type	gene with protein product
Status	Approved
Aliases	TAFI48, SL1
Ensembl gene	ENSG00000143498
Ensembl biotype	protein_coding
OMIM	604903
Entrez	9015

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 9 protein_coding, 3 protein_coding_CDS_not_defined

ENST00000350027, ENST00000352967, ENST00000366890, ENST00000391883, ENST00000465263, ENST00000480065, ENST00000487009, ENST00000925618, ENST00000925619, ENST00000925620, ENST00000972077, ENST00000972078

RefSeq mRNA: 3 — MANE Select: NM_005681 NM_001201536, NM_005681, NM_139352

CCDS: CCDS1531, CCDS1532

Canonical transcript exons

ENST00000352967 — 11 exons

Exon	Start	End
ENSE00001916486	222558312	222558772
ENSE00002277093	222589727	222589933
ENSE00002335396	222563173	222563296
ENSE00002378957	222561364	222561518
ENSE00002704782	222564059	222564125
ENSE00003471270	222584128	222584297
ENSE00003473559	222569510	222569668
ENSE00003578699	222570535	222570665
ENSE00003600844	222579759	222579872
ENSE00003603881	222577445	222577643
ENSE00003686172	222588443	222588565

Expression profiles

Bgee: expression breadth ubiquitous, 220 present calls, max score 94.99.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.2001 / max 199.4382, expressed in 1514 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
17605	2.6444	1220
17604	1.6353	934
17602	0.5122	276
17603	0.4082	198

Top tissues by expression

280 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oocyte	CL:0000023	94.99	gold quality
secondary oocyte	CL:0000655	94.49	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	86.66	gold quality
ventricular zone	UBERON:0003053	85.44	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	85.05	gold quality
ganglionic eminence	UBERON:0004023	84.70	gold quality
cortical plate	UBERON:0005343	82.12	gold quality
embryo	UBERON:0000922	81.98	gold quality
calcaneal tendon	UBERON:0003701	81.43	gold quality
adrenal tissue	UBERON:0018303	78.46	gold quality
monocyte	CL:0000576	77.60	gold quality
leukocyte	CL:0000738	77.25	gold quality
mononuclear cell	CL:0000842	77.16	gold quality
lymph node	UBERON:0000029	76.95	gold quality
stromal cell of endometrium	CL:0002255	76.65	gold quality
islet of Langerhans	UBERON:0000006	76.11	gold quality
right coronary artery	UBERON:0001625	75.78	gold quality
rectum	UBERON:0001052	75.58	gold quality
left ovary	UBERON:0002119	75.52	gold quality
germinal epithelium of ovary	UBERON:0001304	75.39	gold quality
vermiform appendix	UBERON:0001154	75.35	gold quality
ovary	UBERON:0000992	74.99	gold quality
right ovary	UBERON:0002118	74.96	gold quality
granulocyte	CL:0000094	74.87	gold quality
left coronary artery	UBERON:0001626	74.58	gold quality
endocervix	UBERON:0000458	74.39	gold quality
left lobe of thyroid gland	UBERON:0001120	73.92	gold quality
right lobe of thyroid gland	UBERON:0001119	73.89	gold quality
gall bladder	UBERON:0002110	73.76	gold quality
body of uterus	UBERON:0009853	73.58	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.71

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NPM1, TBP, UBTF

miRNA regulators (miRDB)

35 targeting TAF1A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-369-3P	99.85	70.52	2264
HSA-MIR-383-3P	99.85	65.84	1359
HSA-MIR-374C-5P	99.80	72.06	2910
HSA-MIR-655-3P	99.80	72.19	2909
HSA-MIR-323A-3P	99.79	70.30	1739
HSA-MIR-449C-5P	99.78	67.63	1168
HSA-MIR-34B-5P	99.78	67.56	1175
HSA-MIR-187-5P	99.74	70.26	1404
HSA-MIR-2682-5P	99.73	67.38	1055
HSA-MIR-3714	99.71	70.74	2671
HSA-MIR-379-3P	99.69	69.60	1524
HSA-MIR-411-3P	99.69	69.63	1524
HSA-MIR-892A	99.54	68.16	1141
HSA-MIR-582-5P	99.47	70.79	2635

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 50.4% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 3)

• This study identifies the first nuclear import sequence within the TBP-Associated Factor subunits of Selectivity Factor 1. (PMID:15113842)
• The authors demonstrate the interaction of both RNA polymerase I and III with hepatitis delta virus RNA, both in vitro and in human cells. (PMID:19246067)
• TNFAIP8 regulates cisplatin resistance through TAF-Ialpha and promotes malignant progression of esophageal cancer. (PMID:32432789)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	taf1a	ENSDARG00000052471
mus_musculus	Taf1a	ENSMUSG00000072258
rattus_norvegicus	Taf1a	ENSRNOG00000061139

Protein

Protein identifiers

TATA box-binding protein-associated factor RNA polymerase I subunit A — Q15573 (reviewed: Q15573)

Alternative names: RNA polymerase I-specific TBP-associated factor 48 kDa, TATA box-binding protein-associated factor 1A, Transcription factor SL1, Transcription initiation factor SL1/TIF-IB subunit A

All UniProt accessions (2): Q15573, Q5JRA7

UniProt curated annotations — full annotation on UniProt →

Function. Component of the transcription factor SL1/TIF-IB complex, which is involved in the assembly of the PIC (pre-initiation complex) during RNA polymerase I-dependent transcription. The rate of PIC formation probably is primarily dependent on the rate of association of SL1/TIF-IB with the rDNA promoter. SL1/TIF-IB is involved in stabilization of nucleolar transcription factor 1/UBTF on rDNA. Formation of SL1/TIF-IB excludes the association of TBP with TFIID subunits.

Subunit / interactions. Component of the transcription factor SL1/TIF-IB complex, composed of TBP and at least TAF1A, TAF1B, TAF1C and TAF1D. In the complex interacts directly with TBP, TAF1A and TAF1B. Interaction of the SL1/TIF-IB subunits with TBP excludes interaction of TBP with the transcription factor IID (TFIID) subunits. Interacts with UBFT. Interacts with CEBPA (isoform 1 and isoform 4). Part of Pol I pre-initiation complex (PIC), in which Pol I core assembles with RRN3 and promoter-bound UTBF and SL1/TIF-IB complex.

Subcellular location. Nucleus. Nucleolus.

Isoforms (2)

UniProt ID	Names	Canonical?
Q15573-1	1	yes
Q15573-2	2

RefSeq proteins (3): NP_001188465, NP_005672, NP_647603 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR016629	RNA_pol_I_TAF1A/TAFI48_chr	Family
IPR039495	TAF1A	Family
IPR052669	SL1/TIF-IB_Component	Family

Pfam: PF14929

UniProt features (3 total): chain 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q15573-F1	86.29	0.66

Function

Pathways and Gene Ontology

Reactome pathways

12 pathways

ID	Pathway
R-HSA-427359	SIRT1 negatively regulates rRNA expression
R-HSA-427413	NoRC negatively regulates rRNA expression
R-HSA-5250924	B-WICH complex positively regulates rRNA expression
R-HSA-73762	RNA Polymerase I Transcription Initiation
R-HSA-73772	RNA Polymerase I Promoter Escape
R-HSA-73863	RNA Polymerase I Transcription Termination
R-HSA-212165	Epigenetic regulation of gene expression
R-HSA-5250913	Positive epigenetic regulation of rRNA expression
R-HSA-5250941	Negative epigenetic regulation of rRNA expression
R-HSA-73854	RNA Polymerase I Promoter Clearance
R-HSA-73864	RNA Polymerase I Transcription
R-HSA-74160	Gene expression (Transcription)

MSigDB gene sets: 122 (showing top): REACTOME_RNA_POLYMERASE_I_TRANSCRIPTION_INITIATION, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, WEI_MYCN_TARGETS_WITH_E_BOX, DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_UP, DODD_NASOPHARYNGEAL_CARCINOMA_UP, FISCHER_DREAM_TARGETS, MODULE_124, BROWNE_HCMV_INFECTION_14HR_UP, GOCC_TRANSCRIPTION_REGULATOR_COMPLEX, CHEN_HOXA5_TARGETS_9HR_UP, GOCC_NUCLEOLUS, TOOKER_GEMCITABINE_RESISTANCE_DN, GAZDA_DIAMOND_BLACKFAN_ANEMIA_ERYTHROID_DN, GOBP_TRANSCRIPTION_BY_RNA_POLYMERASE_I, PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_6

GO Biological Process (2): transcription by RNA polymerase I (GO:0006360), transcription by RNA polymerase II (GO:0006366)

GO Molecular Function (2): DNA binding (GO:0003677), protein binding (GO:0005515)

GO Cellular Component (6): nucleoplasm (GO:0005654), RNA polymerase transcription factor SL1 complex (GO:0005668), microtubule cytoskeleton (GO:0015630), RNA polymerase I transcription regulator complex (GO:0000120), nucleus (GO:0005634), nucleolus (GO:0005730)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
Negative epigenetic regulation of rRNA expression	2
RNA Polymerase I Promoter Clearance	2
RNA Polymerase I Transcription	2
Gene expression (Transcription)	2
Epigenetic regulation of gene expression	2
Positive epigenetic regulation of rRNA expression	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
DNA-templated transcription	2
nuclear lumen	2
nucleic acid binding	1
binding	1
cellular anatomical structure	1
RNA polymerase I transcription regulator complex	1
cytoskeleton	1
transcription regulator complex	1
nucleolus	1
nuclear protein-containing complex	1
intracellular membrane-bounded organelle	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

1192 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TAF1A	TAF1B	Q53T94	999
TAF1A	TAF1C	Q15572	999
TAF1A	TAF1D	Q9H5J8	996
TAF1A	TBP	P20226	969
TAF1A	POLR1E	Q9GZS1	944
TAF1A	POLR1G	O15446	922
TAF1A	UBTF	P17480	900
TAF1A	POLI	Q9UNA4	898
TAF1A	RRN3	Q9NYV6	870
TAF1A	TAF1	P21675	699
TAF1A	SNAPC3	Q92966	681
TAF1A	TAF12	Q16514	669
TAF1A	SNAPC4	Q5SXM2	669
TAF1A	SNAPC1	Q16533	650
TAF1A	SNAPC2	Q13487	650

IntAct

74 interactions, top by confidence:

A	B	Type	Score
EAF1	ELL2	psi-mi:“MI:0914”(association)	0.840
TSG101	VPS37C	psi-mi:“MI:0914”(association)	0.780
TAF1A	TBP	psi-mi:“MI:0914”(association)	0.740
TBP	TAF1A	psi-mi:“MI:0915”(physical association)	0.740
VAPB	FAM83G	psi-mi:“MI:0914”(association)	0.730
TAF1B	TAF1A	psi-mi:“MI:0915”(physical association)	0.670
RPL14	RRP8	psi-mi:“MI:0914”(association)	0.640
NPM1	MPHOSPH10	psi-mi:“MI:0914”(association)	0.610
NKAPD1	TAF1A	psi-mi:“MI:0915”(physical association)	0.560
MECP2	GTPBP10	psi-mi:“MI:0914”(association)	0.530
TRIM44	ODAD3	psi-mi:“MI:0914”(association)	0.530
ZNF512	ZNF724	psi-mi:“MI:0914”(association)	0.530
EPB41L3	AP3B1	psi-mi:“MI:0914”(association)	0.530
RPL37A	MPHOSPH10	psi-mi:“MI:0914”(association)	0.530
RBM34	NVL	psi-mi:“MI:0914”(association)	0.530
RPL30	RRP8	psi-mi:“MI:0914”(association)	0.530
RPL8	ZBTB24	psi-mi:“MI:0914”(association)	0.530
MAGEB2	GTPBP10	psi-mi:“MI:0914”(association)	0.530
TAF1A	TAF1C	psi-mi:“MI:0914”(association)	0.530
TAF1A	SET	psi-mi:“MI:0915”(physical association)	0.520
SET	TAF1A	psi-mi:“MI:0915”(physical association)	0.520
TAF1A	JMJD6	psi-mi:“MI:0915”(physical association)	0.370
Wdr5	MGA	psi-mi:“MI:0914”(association)	0.350
TBP	DYRK1A	psi-mi:“MI:0914”(association)	0.350
Kif15	CROCC	psi-mi:“MI:0914”(association)	0.350

BioGRID (114): C11orf57 (Two-hybrid), TAF1A (Affinity Capture-MS), TAF1A (Affinity Capture-MS), TAF1A (Affinity Capture-MS), TAF1A (Affinity Capture-MS), TAF1A (Affinity Capture-MS), TAF1A (Affinity Capture-MS), TAF1A (Affinity Capture-MS), TAF1A (Affinity Capture-MS), TAF1A (Affinity Capture-MS), TAF1A (Affinity Capture-MS), TAF1A (Affinity Capture-MS), TAF1A (Affinity Capture-MS), TAF1A (Affinity Capture-MS), TAF1A (Affinity Capture-MS)

ESM2 similar proteins: A1L1K3, A5A6J9, A6H6E9, B0BF33, D3ZSP7, O14879, O88196, P09913, P09914, P97357, Q14AT2, Q14D04, Q15573, Q32NR4, Q3B7U2, Q4R6I5, Q4R6M4, Q4R7V1, Q4V7F0, Q5H9U9, Q5PQQ9, Q5PQS3, Q5U2X2, Q5XIR8, Q5ZKK3, Q5ZLS8, Q60462, Q64112, Q64282, Q64345, Q6AYP3, Q6IQY5, Q7Z3E5, Q80VM3, Q86VD1, Q8C6S9, Q8CHY7, Q8IYW2, Q8K2A7, Q8NA56

Diamond homologs: P97357, Q15573, Q3B7U2

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
TAF1A	“form complex”	“SL1 complex”	binding
TAF1A	“form complex”	“SAGA complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 82 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Selenocysteine synthesis	11	23.2×	1e-10
Negative epigenetic regulation of rRNA expression	5	22.8×	3e-05
Peptide chain elongation	10	22.3×	6e-10
Viral mRNA Translation	10	22.3×	6e-10
PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA	10	22.0×	6e-10
Eukaryotic Translation Termination	10	21.1×	8e-10
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)	10	20.6×	8e-10
ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA	10	20.6×	8e-10

GO biological processes:

GO term	Partners	Fold	FDR
cytoplasmic translation	11	28.3×	6e-11
translation	12	17.1×	9e-10
rRNA processing	8	15.7×	6e-06

Disease & clinical

Clinical variants and AI predictions

ClinVar

66 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	46
Likely benign	4
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1519 predictions. Top by Δscore:

Variant	Effect	Δscore
1:222558677:CAATA:C	donor_gain	1.0000
1:222561359:TGTA:T	donor_loss	1.0000
1:222561360:GTAC:G	donor_loss	1.0000
1:222561420:T:TA	donor_gain	1.0000
1:222561514:GGTTT:G	acceptor_gain	1.0000
1:222561515:GTTT:G	acceptor_gain	1.0000
1:222561516:TTT:T	acceptor_gain	1.0000
1:222561517:TT:T	acceptor_gain	1.0000
1:222561519:C:CC	acceptor_gain	1.0000
1:222563297:C:CC	acceptor_gain	1.0000
1:222569524:T:C	donor_gain	1.0000
1:222569667:ATCT:A	acceptor_loss	1.0000
1:222569668:TC:T	acceptor_loss	1.0000
1:222569669:C:CC	acceptor_gain	1.0000
1:222569669:CT:C	acceptor_loss	1.0000
1:222570530:CTT:C	donor_loss	1.0000
1:222570531:TTA:T	donor_loss	1.0000
1:222570532:TACTT:T	donor_loss	1.0000
1:222570533:A:AC	donor_gain	1.0000
1:222570533:ACTT:A	donor_gain	1.0000
1:222570534:C:CA	donor_gain	1.0000
1:222570534:CT:C	donor_gain	1.0000
1:222570534:CTT:C	donor_gain	1.0000
1:222570534:CTTC:C	donor_gain	1.0000
1:222570534:CTTCT:C	donor_gain	1.0000
1:222570661:CTTAT:C	acceptor_gain	1.0000
1:222570662:TTAT:T	acceptor_gain	1.0000
1:222570663:TAT:T	acceptor_gain	1.0000
1:222570664:ATCTG:A	acceptor_loss	1.0000
1:222570665:TC:T	acceptor_loss	1.0000

AlphaMissense

2999 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:222561469:A:G	W379R	0.994
1:222561469:A:T	W379R	0.994
1:222563213:A:G	W349R	0.991
1:222563213:A:T	W349R	0.991
1:222569580:G:T	A275D	0.988
1:222570564:A:G	W236R	0.988
1:222570564:A:T	W236R	0.988
1:222561479:C:A	R375S	0.987
1:222561479:C:G	R375S	0.987
1:222579866:A:G	W100R	0.987
1:222579866:A:T	W100R	0.987
1:222584211:A:G	W70R	0.987
1:222584211:A:T	W70R	0.987
1:222561467:C:A	W379C	0.985
1:222561467:C:G	W379C	0.985
1:222569625:A:T	L260H	0.985
1:222561490:A:G	W372R	0.984
1:222561490:A:T	W372R	0.984
1:222569514:A:G	L297P	0.984
1:222569625:A:G	L260P	0.983
1:222570553:A:C	F239L	0.983
1:222570553:A:T	F239L	0.983
1:222570555:A:G	F239L	0.983
1:222577592:C:G	A153P	0.981
1:222561457:G:C	H383D	0.980
1:222569588:A:C	N272K	0.979
1:222569588:A:T	N272K	0.979
1:222569613:G:T	A264E	0.979
1:222577618:A:G	L144P	0.979
1:222577495:A:G	L185P	0.978

dbSNP variants (sampled 300 via entrez): RS1000049603 (1:222577081 C>T), RS1000154705 (1:222565190 C>T), RS1000271475 (1:222570316 C>G,T), RS1000276793 (1:222558770 A>G), RS1000307880 (1:222558379 T>C,G), RS1000406721 (1:222591407 A>G), RS1000571308 (1:222584466 T>A), RS1000778732 (1:222584773 C>T), RS1000838584 (1:222571014 T>C), RS1000863796 (1:222556263 G>A), RS1000894698 (1:222583901 A>AG), RS1000917994 (1:222557814 G>GTC), RS1001120243 (1:222590512 A>G), RS1001168545 (1:222563518 A>G), RS1001199926 (1:222563882 G>A)

Disease associations

OMIM: gene MIM:604903 | disease phenotypes: MIM:619433

GenCC curated gene-disease

Disease	Classification	Inheritance
familial isolated dilated cardiomyopathy	Supportive	Autosomal dominant

Mondo (3): dilated cardiomyopathy (MONDO:0005021), cardiomyopathy, familial restrictive, 6 (MONDO:0030330), (MONDO:0015470)

Orphanet (1): Dilated cardiomyopathy (Orphanet:217604)

HPO phenotypes

13 total (13 of 13 shown, HPO-id order):

HPO	Term
HP:0000407	Sensorineural hearing impairment
HP:0000969	Edema
HP:0001635	Congestive heart failure
HP:0001644	Dilated cardiomyopathy
HP:0001727	Thromboembolic stroke
HP:0002875	Exertional dyspnea
HP:0003198	Myopathy
HP:0003457	EMG abnormality
HP:0011675	Arrhythmia
HP:0012378	Fatigue
HP:0012764	Orthopnea
HP:0025169	Left ventricular systolic dysfunction
HP:0100578	Lipoatrophy

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST008154_18	Trunk fat mass	2.000000e-06

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D002311	Cardiomyopathy, Dilated	C14.280.195.160; C14.280.238.070; C16.320.488.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4105882 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, affects expression, decreases expression	5
Benzo(a)pyrene	decreases expression, increases expression	3
Cyclosporine	increases expression	3
Aflatoxin B1	affects expression, increases expression	3
Air Pollutants	decreases expression, increases abundance, increases expression	2
Tetrachlorodibenzodioxin	decreases expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	2
Particulate Matter	decreases expression, increases abundance, increases expression	2
FR900359	increases phosphorylation	1
triphenyl phosphate	affects expression	1
arsenite	affects binding, increases reaction	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	increases expression, increases abundance	1
beta-methylcholine	affects expression	1
CGP 52608	affects binding, increases reaction	1
2-palmitoylglycerol	increases expression	1
monomethylarsonous acid	increases expression	1
erastin	decreases expression	1
abrine	increases expression	1
jinfukang	affects cotreatment, decreases expression	1
Arsenic	increases expression, increases abundance	1
Cannabidiol	affects cotreatment, decreases expression	1
Cisplatin	affects cotreatment, decreases expression	1
Cuprizone	affects cotreatment, decreases expression	1
Estradiol	affects expression	1
Formaldehyde	decreases expression	1
Nickel	increases expression	1
Quercetin	decreases expression	1
Theophylline	increases expression	1
Tobacco Smoke Pollution	increases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4053076	Binding	Inhibition of human His tagged TAF1A incubated for 30 mins followed by addition of biotinylated peptide and further incubation for 30 mins measured by AlphaScreen assay	Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo Studies. — J Med Chem

Cellosaurus cell lines

3 cell lines: 3 embryonic stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A6Y1	SEES3-1V human TAF1A, clone1	Embryonic stem cell	Male
CVCL_A6Y2	SEES3-1V human TAF1A, clone2	Embryonic stem cell	Male
CVCL_A6Y3	SEES3-1V human TAF1A, clone3	Embryonic stem cell	Male

Clinical trials (associated diseases)

158 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00374465	PHASE4	UNKNOWN	Therapy With Verapamil or Carvedilol in Chronic Heart Failure
NCT01293903	PHASE4	COMPLETED	Study of Qiliqiangxin Capsule to Treat Dilated Cardiomyopathy
NCT01557140	PHASE4	COMPLETED	A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy
NCT01917149	PHASE4	COMPLETED	Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy
NCT02115581	PHASE4	COMPLETED	Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy
NCT06236022	PHASE4	RECRUITING	The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus
NCT00333827	PHASE3	COMPLETED	Cell Therapy In Dilated Cardiomyopathy
NCT00505154	PHASE3	COMPLETED	Effect of Rosuvastatin on Left Ventricular Remodeling
NCT01223703	PHASE3	COMPLETED	PUFAs and Left Ventricular Function in Heart Failure
NCT01583114	PHASE3	TERMINATED	PREclinical Mutation CARriers From Families With DIlated Cardiomyopathy and ACE Inhibitors
NCT01914081	PHASE3	UNKNOWN	Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside
NCT02989181	PHASE3	UNKNOWN	Continues Positive Airway Pressure Treatment for Patients With Dilated Cardiomyopathy and Obstructive Sleep Apnea
NCT03439514	PHASE3	TERMINATED	A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation
NCT05237323	PHASE3	COMPLETED	Micophenolate Mofetil Versus Azathioprine in Myocarditis
NCT05849766	PHASE3	COMPLETED	Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction
NCT06250257	PHASE3	RECRUITING	Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age
NCT00629018	PHASE2	COMPLETED	Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy
NCT00629096	PHASE2	COMPLETED	Intracoronary Infusion of Autologous Bone Marrow Cells for Treatment of Idiopathic Dilated Cardiomyopathy
NCT00765518	PHASE2	COMPLETED	Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)
NCT00847964	PHASE2	COMPLETED	Safety and Feasibility of Algisyl-LVR™ as a Method of Left Ventricular Restoration in Patients With DCM Undergoing Open-heart Surgery
NCT01020968	PHASE2	COMPLETED	Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy
NCT01302171	PHASE2	COMPLETED	Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy
NCT01350310	PHASE2	COMPLETED	Safety and Efficacy Study of Intramyocardial Stem Cell Therapy in Patients With Dilated Cardiomyopathy
NCT02133911	PHASE2	COMPLETED	A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy
NCT03071653	PHASE2	SUSPENDED	Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study
NCT03572660	PHASE2	ACTIVE_NOT_RECRUITING	Use of Bone Marrow Derived Stem Cell and G-CSF With Circulatory Assistance in the Treatment of DCM
NCT03775070	PHASE2	COMPLETED	Simvastatin Therapy in Patients With Dilated Cardiomyopathy.
NCT04405804	PHASE2	UNKNOWN	Early Administration of Ivabradine in Children With Heart Failure
NCT05410873	PHASE2	COMPLETED	Examining the Effects of Mitochondrial Oxidative Stress in DCM
NCT06632834	PHASE2	RECRUITING	Outcome-targeted Therapy: Principle and Outcome Evaluation: Clinical Study and Phenotype-genotype Correlation
NCT00585546	PHASE1	TERMINATED	Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure
NCT02293603	PHASE1	UNKNOWN	Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC)
NCT03062956	PHASE1	COMPLETED	A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491
NCT03129568	PHASE1	COMPLETED	Transcoronary Infusion of Cardiac Progenitor Cells in Pediatric Dilated Cardiomyopathy
NCT04982081	PHASE1	UNKNOWN	Treating Congestive HF With hiPSC-CMs Through Endocardial Injection
NCT06381466	PHASE1	TERMINATED	A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.
NCT06464588	PHASE1	RECRUITING	A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)
NCT06902896	PHASE1	COMPLETED	Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy
NCT07137338	PHASE1	RECRUITING	A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy
NCT07241104	PHASE1	RECRUITING	A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy